title: Chemo-radiotherapy in non-small cell lung cancer: the role of gemcitabine.
abstract: Gemcitabine (2'-2'-difluorodeoxycytidine) is a well-known cytotoxic drug and a potent radio-enhancer. We herein report the in vitro evidence of its activity, and the clinical experiences when this drug is administered concurrently with radiation. The phase I-II trials are analyzed, focusing on the recent ability to deliver irradiation with low incidence of side effects.
authors.affiliation: Radiotherapy Unit, University Campus Bio-Medico, Rome, Italy. l.trodella@unicampus.it
authors.forename: L
authors.initials: L
authors.lastname: Trodella
authors.forename: R M
authors.initials: RM
authors.lastname: D'Angelillo
authors.forename: S
authors.initials: S
authors.lastname: Ramella
authors.forename: F
authors.initials: F
authors.lastname: Cellini
authors.forename: M
authors.initials: M
authors.lastname: Ciresa
authors.forename: A
authors.initials: A
authors.lastname: Cesario
authors.forename: P
authors.initials: P
authors.lastname: Granone
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy / Q000532:radiotherapy*; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D003841:Deoxycytidine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000532:radiotherapy*; D020360:Neoadjuvant Therapy; D011838:Radiation-Sensitizing Agents / Q000627:therapeutic use*; D000093542:Gemcitabine
chemical_list: D011838:Radiation-Sensitizing Agents; D003841:Deoxycytidine; D000093542:Gemcitabine